NASDAQ:ADMS - Adamas Pharmaceuticals Stock Price, News & Analysis

$6.42
+0.14 (+2.23 %)
(As of 08/16/2019 04:00 PM ET)
Today's Range
$6.25
Now: $6.42
$6.72
50-Day Range
$5.76
MA: $6.05
$6.65
52-Week Range
$4.20
Now: $6.42
$23.36
Volume302,900 shs
Average Volume339,076 shs
Market Capitalization$178.28 million
P/E RatioN/A
Dividend YieldN/A
Beta1.69
Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADMS
CUSIPN/A
Phone510-450-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$34.05 million
Book Value$1.54 per share

Profitability

Net Income$-131,000,000.00
Net Margins-241.41%

Miscellaneous

Employees159
Market Cap$178.28 million
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable

Receive ADMS News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMS and its competitors with MarketBeat's FREE daily newsletter.


Adamas Pharmaceuticals (NASDAQ:ADMS) Frequently Asked Questions

What is Adamas Pharmaceuticals' stock symbol?

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

How were Adamas Pharmaceuticals' earnings last quarter?

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) announced its quarterly earnings data on Thursday, August, 8th. The specialty pharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.98) by $0.08. The specialty pharmaceutical company earned $12.69 million during the quarter, compared to analysts' expectations of $12.62 million. Adamas Pharmaceuticals had a negative net margin of 241.41% and a negative return on equity of 149.97%. View Adamas Pharmaceuticals' Earnings History.

When is Adamas Pharmaceuticals' next earnings date?

Adamas Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Adamas Pharmaceuticals.

What price target have analysts set for ADMS?

9 brokers have issued twelve-month price objectives for Adamas Pharmaceuticals' stock. Their forecasts range from $5.00 to $55.00. On average, they expect Adamas Pharmaceuticals' share price to reach $23.8750 in the next year. This suggests a possible upside of 271.9% from the stock's current price. View Analyst Price Targets for Adamas Pharmaceuticals.

What is the consensus analysts' recommendation for Adamas Pharmaceuticals?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Adamas Pharmaceuticals.

Has Adamas Pharmaceuticals been receiving favorable news coverage?

News articles about ADMS stock have trended negative this week, InfoTrie reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Adamas Pharmaceuticals earned a news sentiment score of -2.3 on InfoTrie's scale. They also gave news coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Adamas Pharmaceuticals.

Are investors shorting Adamas Pharmaceuticals?

Adamas Pharmaceuticals saw a drop in short interest during the month of July. As of July 31st, there was short interest totalling 3,816,300 shares, a drop of 16.7% from the June 30th total of 4,583,100 shares. Based on an average trading volume of 386,200 shares, the days-to-cover ratio is currently 9.9 days. Approximately 17.4% of the company's stock are sold short. View Adamas Pharmaceuticals' Current Options Chain.

Who are some of Adamas Pharmaceuticals' key competitors?

What other stocks do shareholders of Adamas Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Sangamo Therapeutics (SGMO), Exelixis (EXEL), Omeros (OMER), Synergy Pharmaceuticals (SGYP), TG Therapeutics (TGTX), ACADIA Pharmaceuticals (ACAD), Century Aluminum (CENX), Flexion Therapeutics (FLXN) and Lumentum (LITE).

Who are Adamas Pharmaceuticals' key executives?

Adamas Pharmaceuticals' management team includes the folowing people:
  • Dr. Gregory T. Went, Co-Founder, Chairman & CEO (Age 55)
  • Mr. Alfred G. Merriweather, Chief Financial Officer (Age 65)
  • Mr. Christopher B. Prentiss, Chief Accounting Officer (Age 44)
  • Ashleigh Barreto, Director of Corp. Communications & Investor Relations
  • Ms. Jennifer J. Rhodes, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 49)

Who are Adamas Pharmaceuticals' major shareholders?

Adamas Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.90%), Stonepine Capital Management LLC (5.13%), Vanguard Group Inc. (3.71%), Emerald Advisers LLC (2.54%), Emerald Mutual Fund Advisers Trust (2.24%) and Deltec Asset Management LLC (2.00%). Company insiders that own Adamas Pharmaceuticals stock include Alfred G Merriweather, Christopher B Prentiss, Gregory T Went, Jennifer J Rhodes, Rajiv Patni and Richard King. View Institutional Ownership Trends for Adamas Pharmaceuticals.

Which major investors are selling Adamas Pharmaceuticals stock?

ADMS stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Granite Investment Partners LLC, Bank of New York Mellon Corp and Bingham Osborn & Scarborough LLC. Company insiders that have sold Adamas Pharmaceuticals company stock in the last year include Alfred G Merriweather, Christopher B Prentiss, Gregory T Went and Jennifer J Rhodes. View Insider Buying and Selling for Adamas Pharmaceuticals.

Which major investors are buying Adamas Pharmaceuticals stock?

ADMS stock was purchased by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, BlackRock Inc., Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Price T Rowe Associates Inc. MD, Worth Venture Partners LLC, Parametric Portfolio Associates LLC and Fisher Asset Management LLC. View Insider Buying and Selling for Adamas Pharmaceuticals.

How do I buy shares of Adamas Pharmaceuticals?

Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Adamas Pharmaceuticals' stock price today?

One share of ADMS stock can currently be purchased for approximately $6.42.

How big of a company is Adamas Pharmaceuticals?

Adamas Pharmaceuticals has a market capitalization of $178.28 million and generates $34.05 million in revenue each year. The specialty pharmaceutical company earns $-131,000,000.00 in net income (profit) each year or ($4.87) on an earnings per share basis. Adamas Pharmaceuticals employs 159 workers across the globe.View Additional Information About Adamas Pharmaceuticals.

What is Adamas Pharmaceuticals' official website?

The official website for Adamas Pharmaceuticals is http://www.adamaspharma.com/.

How can I contact Adamas Pharmaceuticals?

Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected]


MarketBeat Community Rating for Adamas Pharmaceuticals (NASDAQ ADMS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  336 (Vote Outperform)
Underperform Votes:  290 (Vote Underperform)
Total Votes:  626
MarketBeat's community ratings are surveys of what our community members think about Adamas Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel